159 related articles for article (PubMed ID: 26616174)
61. Genome-scale metabolic model of the rat liver predicts effects of diet restriction.
Baloni P; Sangar V; Yurkovich JT; Robinson M; Taylor S; Karbowski CM; Hamadeh HK; He YD; Price ND
Sci Rep; 2019 Jul; 9(1):9807. PubMed ID: 31285465
[TBL] [Abstract][Full Text] [Related]
62. Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas.
Rosario SR; Long MD; Affronti HC; Rowsam AM; Eng KH; Smiraglia DJ
Nat Commun; 2018 Dec; 9(1):5330. PubMed ID: 30552315
[TBL] [Abstract][Full Text] [Related]
63. Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism.
Ortmayr K; Dubuis S; Zampieri M
Nat Commun; 2019 Apr; 10(1):1841. PubMed ID: 31015463
[TBL] [Abstract][Full Text] [Related]
64. Repression of Cell-to-Matrix Adhesion by Metformin Chloride Supports Its Anti-Metastatic Potential in an In Vitro Study on Metastatic and Non-Metastatic Cancer Cells.
Aftab S; Khalid Z; Shakoori AR
Crit Rev Eukaryot Gene Expr; 2022; 32(2):91-105. PubMed ID: 35381133
[TBL] [Abstract][Full Text] [Related]
65. Patient- and Cell Type-Specific Heterogeneity of Metformin Response.
Asiedu MK; Barron M; Aubry MC; Wigle DA
Basic Clin Pharmacol Toxicol; 2018 Feb; 122(2):214-222. PubMed ID: 28862803
[TBL] [Abstract][Full Text] [Related]
66. A Metabolic Pattern in Healthy Subjects Given a Single Dose of Metformin: A Metabolomics Approach.
Dahabiyeh LA; Mujammami M; Arafat T; Benabdelkamel H; Alfadda AA; Abdel Rahman AM
Front Pharmacol; 2021; 12():705932. PubMed ID: 34335266
[TBL] [Abstract][Full Text] [Related]
67. Protocol for analyzing energy metabolic pathway dependency in human liver cancer cell lines.
Islam SR; Maity S; Chakrabarti O; Manna SK
STAR Protoc; 2024 Jun; 5(2):102964. PubMed ID: 38507415
[TBL] [Abstract][Full Text] [Related]
68. Metabolic therapies inhibit tumor growth in vivo and in silico.
da Veiga Moreira J; Hamraz M; Abolhassani M; Schwartz L; Jolicœur M; Peres S
Sci Rep; 2019 Feb; 9(1):3153. PubMed ID: 30816152
[TBL] [Abstract][Full Text] [Related]
69. Differential effects of metformin on reductive activity and energy production in pituitary tumor cells compared to myogenic precursors.
Tulipano G; Paghera S; Missale C; Giustina A
Endocrine; 2020 Sep; 69(3):604-614. PubMed ID: 32557328
[TBL] [Abstract][Full Text] [Related]
70. Nuclear Magnetic Resonance-Based Metabolomic Analysis of the Anticancer Effect of Metformin Treatment on Cholangiocarcinoma Cells.
Zhang J; Hang C; Jiang T; Yi S; Shao W; Li W; Lin D
Front Oncol; 2020; 10():570516. PubMed ID: 33330044
[TBL] [Abstract][Full Text] [Related]
71. Preface.
Witty DR; Cox B
Prog Med Chem; 2018; 57(1):ix-x. PubMed ID: 29680152
[No Abstract] [Full Text] [Related]
72. Author Correction: Metformin treatment response is dependent on glucose growth conditions and metabolic phenotype in colorectal cancer cells.
Alhourani AH; Tidwell TR; Bokil AA; Røsland GV; Tronstad KJ; Søreide K; Hagland HR
Sci Rep; 2022 Jan; 12(1):1869. PubMed ID: 35091657
[No Abstract] [Full Text] [Related]
73. Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis.
Wang J; Li G; Wang Y; Tang S; Sun X; Feng X; Li Y; Bao G; Li P; Mao X; Wang M; Liu P
Oncotarget; 2015 Dec; 6(42):44579-92. PubMed ID: 26625311
[TBL] [Abstract][Full Text] [Related]
74. Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis.
Griss T; Vincent EE; Egnatchik R; Chen J; Ma EH; Faubert B; Viollet B; DeBerardinis RJ; Jones RG
PLoS Biol; 2015 Dec; 13(12):e1002309. PubMed ID: 26625127
[TBL] [Abstract][Full Text] [Related]
75. Metformin inhibits growth of lung adenocarcinoma cells by inducing apoptosis via the mitochondria-mediated pathway.
Wang J; Gao Q; Wang D; Wang Z; Hu C
Oncol Lett; 2015 Sep; 10(3):1343-1349. PubMed ID: 26622674
[TBL] [Abstract][Full Text] [Related]
76. Anti-Tumor Activity of Yuanhuacine by Regulating AMPK/mTOR Signaling Pathway and Actin Cytoskeleton Organization in Non-Small Cell Lung Cancer Cells.
Kang JI; Hong JY; Lee HJ; Bae SY; Jung C; Park HJ; Lee SK
PLoS One; 2015; 10(12):e0144368. PubMed ID: 26656173
[TBL] [Abstract][Full Text] [Related]
77. Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative.
Gong Z; Aragaki AK; Chlebowski RT; Manson JE; Rohan TE; Chen C; Vitolins MZ; Tinker LF; LeBlanc ES; Kuller LH; Hou L; LaMonte MJ; Luo J; Wactawski-Wende J
Int J Cancer; 2016 Apr; 138(8):1915-27. PubMed ID: 26616262
[TBL] [Abstract][Full Text] [Related]
78. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
Higurashi T; Hosono K; Takahashi H; Komiya Y; Umezawa S; Sakai E; Uchiyama T; Taniguchi L; Hata Y; Uchiyama S; Hattori A; Nagase H; Kessoku T; Arimoto J; Matsuhashi N; Inayama Y; Yamanaka S; Taguri M; Nakajima A
Lancet Oncol; 2016 Apr; 17(4):475-483. PubMed ID: 26947328
[TBL] [Abstract][Full Text] [Related]
79. Box Behnken optimization of cubosomes for enhancing the anticancer activity of metformin: Design, characterization, and in-vitro cell proliferation assay on MDA-MB-231 breast and LOVO colon cancer cell lines.
Zaki RM; Alkharashi LA; Sarhan OM; Almurshedi AS; Aldosari BN; Said M
Int J Pharm X; 2023 Dec; 6():100208. PubMed ID: 37680878
[TBL] [Abstract][Full Text] [Related]
80. Metformin is a metabolic modulator and radiosensitiser in rectal cancer.
Buckley CE; O'Brien RM; Nugent TS; Donlon NE; O'Connell F; Reynolds JV; Hafeez A; O'Ríordáin DS; Hannon RA; Neary P; Kalbassi R; Mehigan BJ; McCormick PH; Dunne C; Kelly ME; Larkin JO; O'Sullivan J; Lynam-Lennon N
Front Oncol; 2023; 13():1216911. PubMed ID: 37601689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
